Best Startup
At Best Startup UK we track over 130,000 UK startups and over 500,000 people who hold key positions in these companies. We use this directory of startups to highlight top employees, founders and board members we think deserve more appreciation than they are currently getting.
This list showcases the top London based CEO’ operating in the Therapeutics space. If you think a CEO’ is missing from this list, feel free to contact our editor on editor@beststartup.co.uk.
The individuals on this list have been included because of exceptional performance in one of the following categories:
- Innovation – Operating as a key part in an extremely innovative business or startup.
- Growth – Operating as a key figure in the growth and upscale of a market leading business or startup.
- Management – Showing exceptional management skills.
- Societal impact – Putting their business on the map for their positive societal or environmental impact.
Our Data – We source our data from OSINT (open source intelligence) and public directories such as Companies House UK, Crunchbase, SemRush and many more. The data from these sources should be treated with a degree of caution and verified yourself.
Siro Perez
Co-Founder & CEO of Molecular Warehouse
Follow Siro Perez:
About IP Group, Kira Biotech, Molecular Warehouse: Molecular Warehouse is creating a world where most diseases are prevented, by giving people the power of molecular diagnostics and mHealth.
_______
Peter Hames
Co-Founder & CEO of Big Health
Peter Hames is CEO of Big Health, a digital medicine company he co-founded with clinical psychologist Prof Colin Espie (University of Oxford). Big Health creates automated behavioral medicine programs fuelled by tracked data, and was inspired by Peter’s difficulty in getting access to evidence-based non-drug solutions to his own insomnia. Big Health’s first product, Sleepio, is a digital sleep improvement program featuring personalized Cognitive Behavioral Therapy (CBT) techniques, delivered by virtual animated sleep expert The Prof and his narcoleptic dog Pavlov. In the world’s first placebo-controlled randomised trial for an intervention of its kind, Sleepio was shown to be comparable in effectiveness to face-to-face therapy.
Follow Peter Hames:
About Big Health, Lucky Voice, NHS England, Sleepio: Big Health is a digital therapeutics company operating a healthcare portal to offer behavioral programs for mental health issues.
James Field
CEO & Founder of LabGenius
James is founder and CEO of LabGenius. James completed his PhD studies at Imperial College London where his research was focused on re-engineering protein nanocages for biotechnological applications. Prior to his PhD, James completed a BSc in Biology with Microbiology and an MRes in Systems and Synthetic Biology, at Imperial College London. James is an active member of the synthetic biology community having participated in the iGEM competition both as an undergraduate (2009), advisor (2011) and judge (2016). In 2017, James was awarded the BBSRC Innovator of the Year award for early career impact. James is also a fellow of the prestigious Synthetic Biology Leadership Excellence Accelerator Program (LEAP).
Follow James Field:
About LabGenius: LabGenius is a biopharmaceutical company developing protein therapeutics using a machine learning-driven evolution engine.
Susan Greenfield
Founder & CEO of Neuro-Bio
Follow Susan Greenfield:
About Neuro-Bio: Neuro-Bio is a British pharmaceutical company
Baroness Susan Greenfield
CEO & Founder of Neuro-Bio
Susan Greenfield is a neuroscientist, writer, and broadcaster. She has been awarded 30 Honorary Degrees from British and foreign universities and heads a multi-disciplinary research group exploring novel brain mechanisms linked to neurodegenerative diseases such Alzheimer’s and Parkinson’s. She is a Senior Research Fellow at Lincoln College, Oxford and has currently co-founded a biotech company developing a novel approach to neurodegenerative disorders (Neuro-Bio Ltd). In addition, she has published a neuroscientific theory of consciousness,’The Private Life of the Brain’ (2003) and developed a keen interest in the impact of modern technologies on how young people think and feel. This was discussed in her book, ‘ID: The Quest for Identity in the 21st Century’ (2008). In 1998 she received the Michael Faraday Medal from the Royal Society, was awarded a CBE in the Millennium New Year’s Honours List and was granted a non-political Life Peerage in 2001. In 2000 she was elected to an Honorary Fellowship of the Royal College of Physicians and in 2007 to an Honorary Fellowship of the Royal Society of Edinburgh. She was appointed Chancellor of Heriot Watt University in 2005. Further recognition of her work includes L’Ordre National de la Légion d’Honneur from the French Government, and the American Academy of Achievement Golden Plate Award, both received in 2003. Susan was also awarded the Australian Medical Research Society Medal in 2010. In 2011, Susan joined the Advisory Board of the Kusuma School of Biological Sciences at the Indian Institute for Technology, Delhi. In 2012, Susan was offered the Honorary Fellowship of the Institute of Risk Management and also became a Vice Patron of POWER International. Further on in 2012, Susan was selected to serve as the Parliamentary Patron of the Westminster Higher Education Forum, alongside of continuing to be a Parliamentary Patron of the Westminster Education Forum. Continuing through 2012, Susan bacame a Governor of The Florey Institute for Neuroscience and Mental Health and also started to suport the IAB (the International Advisory Board). In January 2014, she was included in the Debrett’s 500, “a recognition of the most influential and inspiring 500 people in Britain.”. Most recently, in July 2014, Susan was awarded as an Honorary Doctorate at Middlesex University.
Follow Baroness Susan Greenfield:
About Neuro-Bio: Neuro-Bio is a British pharmaceutical company
Elena Mustatea
CEO of Bold Health
Elena is an Associate at Atomico. As part of our London team, she focuses on sourcing and evaluating investment opportunities, as well as supporting Atomico and its portfolio companies on operational projects and research. Before joining Atomico, Elena worked in investment banking at J.P. Morgan in London, where she advised various EMEA internet, telecoms, media and technology companies in financing and M&A processes. Elena started her career as a management consultant with Oliver Wyman in Dubai covering Middle Eastern telecoms and public sector companies, with a focus on strategy, business planning and risk management projects. Elena holds a Bachelor of Arts in Economics from Dartmouth College in the US, and studied abroad in Germany, France, and Italy.
Follow Elena Mustatea:
About Bold Health: Bold Health is a specialty telemedicine company that offers best-in-class integrative care for Gastrointestinal (GI) conditions.
Keith Blundy
CEO of Storm Therapeutics
Follow Keith Blundy:
About Storm Therapeutics: Targeting pathways that modify RNA to deliver novel cancer therapeutics
Chris Martin
CEO of ADC Therapeutics
Chris Martin, DPhil, is the former CEO and co-founder ADC Therapeutics, a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates.
Follow Chris Martin:
About ADC Therapeutics: ADC Therapeutics develops antibody drug conjugates and non-antibody drug conjugate products.
Philip M. Toleikis
President & CEO of Sernova
Dr. Toleikis is President and Chief Executive Officer of Sernova Corp since April 2009. From 2006 until 2009, Dr. Toleikis consulted for multiple device, combination product and pharmaceutical companies. From 1996 to 2006 he held multiple roles at Angiotech Pharmaceuticals, Inc. including Vice President, Research and Development – Pharmacology and Drug Screening where he built a product development team of over 50 scientists and was responsible for multiple corporate and academic product development collaborations. While at Sernova, Dr. Toleikis has secured over $60 million in various forms of financings, including equity raises and multiple non-dilutive grants and has been responsible for negotiating a worldwide exclusive license with UHN and University of Miami for its stem cell derived technologies as well as developing business relationships and or collaborations with multiple pharmaceutical and academic institutions involving its Cell Pouch™ device and cell technologies. Dr. Toleikis is an author of over 100 patent applications ande issued patents, and multiple scientific publications involving transplantation, metabolic, cardiovascular, oncology, and autoimmune disease. He obtained his Ph.D. in Medicine, Pharmacology and Therapeutics from the University of British Columbia, his M.Sc. at the University of Michigan and B.A. at the University of Vermont.
Follow Philip M. Toleikis:
About Sernova: Sernova develops regenerative medicine therapeutic technologies for treatment of chronic metabolic diseases.
George Frodsham
Founder & CEO of MediSieve
George Frodsham founded MediSieve after being awarded his PhD in biochemical engineering from University College London (UCL), during which he developed the magnetic blood filter. As well as being a physicist and engineer, George is an entrepreneur. George was awarded a BBSRC Enterprise Fellowship from the Royal Society of Edinburgh in 2014. Since 1996, only 180 individuals have benefited from this highly competitive and prestigious programme. George has also completed the Entrepreneurship Summer School programme at the London Business School. This equipped him to research target markets and industries and turn his visions into viable businesses.
Follow George Frodsham:
About MediSieve: MediSieve is a therapeutics company developing a platform technology for the treatment of blood-borne diseases.
Anna Perdrix Rosell
Co-Founder & Co-CEO of Sixfold Bioscience
Anna Perdrix Rosell is the Co-Founder & Co-CEO at Sixfold Bioscience.
Follow Anna Perdrix Rosell:
About Sixfold Bioscience: Sixfold Bioscience develops and researches on biotechnology advances for RNA therapies.
Robert Thong
Chairman & Chief Executive Officer of Multiomic Health
Robert has made the art of consulting his life’s work. As Co-Founder and Executive Chairman of Unleash, he applies a wealth of experience to his personal mission: creating world-beating organisations. A supportive advisor to senior executives, Robert combines experienced know-how with an open mindset, delivering results that keep his clients coming back for more. Moving to the UK from Malaysia as a super-smart, teenage maths whiz, Robert started his career as an actuary. Finding business more interesting than statistical models, it wasn’t long before he decided to pursue the MBA that would introduce him to the world of management consulting. Initially focusing on analytical strategy development and operations improvement across various industries, Robert was soon drawn towards managing strategic change in R&D-driven organisations. Robert’s deep understanding of the inner workings of the pharmaceutical industry combined with his appreciation of a senior executive’s daily pressures, is a rare find indeed. He has not only been the pharmaceutical practice head in major consultancies, held P&L accountability and board positions, Robert has also spent much of his time on the ground understanding the real-life issues facing clients in laboratories, factories, pharmacies and physician offices. Coming from an analytical background himself, Robert had to learn in practice about the importance of managing change and engaging people to ensure lasting results, and was inspired to help clients do the same. Robert is dedicated to his clients winning long-term. After founding a boutique consultancy focused on the management practices of small-to-mid sized outfits competing with Big Pharmas, he decided to follow his true calling: guiding leaders and organisations of all types and sizes to success through people-driven strategy execution.
Follow Robert Thong:
About Multiomic Health, Selvedge Venture: Multiomic Health is building a precision therapeutics discovery platform for metabolic syndrome diseases
Malcolm Weir
Founder & CEO of Heptares Therapeutics
Former Visiting Professor of Biochemistry at Imperial College, London. Former Head of the Molecular Sciences Division of Glaxo Wellcome Inc. (present Glaxo Smithkline plc.) Former CEO of Inpharmatica Ltd.（present Galapagos NV). Founder and CEO of Heptares Therapeutics Ltd.
Follow Malcolm Weir:
About Heptares Therapeutics, Sosei Group: Heptares Therapeutics develops novel, small-molecule drugs for G-protein-coupled receptors (GPCRs).
Herbert Oakes
Founder & CEO of NOXSUDOR THERAPEUTICS LIMITED
Herbert Oakes, non-executive director, is an investment banker and builder of high technology life sciences companies. He is currently a Managing Director of Oakes, Lyman & Co. Limited an investment banking firm specialising in high-tech healthcare; a Managing director of Hycroft Advisors, a global investment banking firm specialising in arranging capital for private equity partnerships; and CEO of NoxSudor Therapeutics Limited, a start-up medical business developing a therapy for hot flashes and night sweats for menopausal women. He is an advisor of Wilton Corporate Finance Limited.
Follow Herbert Oakes:
About NOXSUDOR THERAPEUTICS LIMITED: First prescription medical device to control sweating
Allison Jeynes-Ellis
Co-Founder & CEO of Avillion
Over 20 years of senior leadership experience in the pharmaceutical industry. Significant global drug development experience and successful EU and US drug approvals across a range of therapeutic areas. Leadership of global clinical development teams for Phase 3, including CRO selection and management. Strong networks within the pharma industry and relevant regulatory bodies
Follow Allison Jeynes-Ellis:
About Avillion: Avillion LLP, a London, UK-based company that focuses on clinical co-development of therapeutics.
Sandra Schembri
Chief Executive Officer of Nordoff Robbins Music Therapy
Follow Sandra Schembri:
About Nordoff Robbins Music Therapy: Nordoff Robbins Music Therapy is a non-profit organization that offers music therapy services for free to reduce anxiety and comfort.
Davidson Ateh
Co-Founder & CEO of BioMoti
Davidson is an entrepreneur operating in the life sciences. He has an interdisciplinary scientific background in bioengineering and was a past recipient of the prestigious Royal Society of Edinburgh/BBSRC Enterprise Fellowship. Davidson has significant technology translation experience including proof-of-concept studies, IP protection, non-dilutive grant applications, partnering, licensing and raising investment. He has won awards for his scientific and commercial activities. Davidson is a co-inventor of the Oncojan™ drug delivery platform, co-founder of BioMoti and leads product and business development activities.
Follow Davidson Ateh:
About BioMoti: BioMoti seeks to transform the treatment of cancer by targeted delivery of therapeutics to the intracellular space of cancer cells
Charles Large
Founder and CEO of Autifony Therapeutics
Charles Large received his first degree and PhD from the University of Bristol and has more than 20 years of experience of drug discovery and development in the pharmaceutical industry. Before founding Autifony, he was Director of Molecular and Cellular Biology within the Neuroscience Centre of Excellence for Drug Discovery at GlaxoSmithKline, and has worked on programs focused on schizophrenia, Alzheimer’s disease, epilepsy, bipolar disorder, and major depression. He is an expert on drugs that modulate voltage gated ion channels and their application to neurological and psychiatric disorders. He has built up a reputation in the field of sodium channel blocking drugs, and has collaborated widely with academic groups. He has authored over 50 papers, book chapters and patents relating to ion channel modulators.
Follow Charles Large:
About Autifony Therapeutics: Autifony Therapeutics is a biotechnology company developing medicines to treat hearing disorders such as hearing loss and tinnitus.
Hakim Yadi
CEO & Co-Founder of Closed Loop Medicine
Hakim Yadi is the CEO and Co-Founder at Closed Loop Medicine.
Follow Hakim Yadi:
About : Developing personalised digital healthcare solutions to improve outcomes for patients and clinicians
Isabel Van De Keere
Founder and CEO of Immersive Rehab
Isabel is an experienced innovation strategist & manager, researcher, product designer, experimentalist, and collaborator across disciplines. She is passionate about science, healthcare technologies, digital health, immersive technologies (VR/AR) and its applications in healthcare, using tech for good, social entrepreneurship, and promoting women in tech.
Follow Isabel Van De Keere:
About Immersive Rehab: IR creates interactive physiotherapy programmes in Virtual Reality that improve the effectiveness of physical & neuro-rehabilitation.
